undamentalytics Newsletter
Sign in

Fate Therapeutics Inc cash flow statement

In fiscal 2025, Fate Therapeutics Inc's operations generated −$106m of cash; it spent $6.0m on capital projects, leaving free cash flow of −$112m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−12−13−15−18−30−37−39−83−39−163−248−132−123−106−102
Depreciation and amortisation11111112361418191312
Stock-based pay00223461731547943412518
Capital spending01010227551366164
Free cash flow−12−14−16−20−30−39−41−91−44−214−284−138−124−112−106
Free cash flow after stock pay−12−14−17−22−33−42−47−108−75−268−363−182−165−137−123
Share buybacks0——————————————
Shares issued0005—43135162189412—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FATE vs HCWBCGON vs FATEFATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fate Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fate Therapeutics Inc.